UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~May~~June 257, 2016

SCRIPSAMERICA, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-54550	26-2598594
(State of Incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)

1094 Main Avenue, Suite A, Clifton, NJ	07011
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (800) 957-7622

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

~~Financing~~On ~~Activities~~Tuesday, June 7, 2016, federal agents executed a search warrant for various records of Main Avenue Pharmacy, Inc. (“Main Avenue”) pertaining to the securing, filling, billing and delivery of all prescriptions, together with correspondence and business records from January, 2014 to present with respect thereto. This included paper and electronic records.

~~On May 3, 2016, in its Form 8-K filing, Registrant discussed certain inter-related financing matters resulting from certain actions being taken by Express Scripts, Inc. (“ESI”).~~ In ~~summary~~addition, ~~due~~ ~~to an investigation related to prescriptions written by~~ a ~~telemarketing~~subpoena ~~doctor~~was ~~and~~served ~~filled~~calling ~~by Registrant’s subsidiary, Main Avenue Pharmacy, Inc. (“Main Avenue”), Express Scripts, Inc., as the representative of the various health insurance carriers who paid~~ for ~~such~~records ~~prescriptions,~~not ~~was withholding approximately $3.55 million of funds owing to Main Avenue and indicated~~present ~~that~~at ~~it might demand reimbursement by Main Avenue. The actions being taken by ESI caused a technical default under~~ the ~~financing documents covering borrowings against~~ Main Avenue’s ~~accounts receivable, of which Main Avenue received notice from the lender on April 26, 2016~~premises.

~~Main~~The ~~Avenue~~documents ~~received~~sought and filled prescriptions written by the doctor from the fourth quarter of 2014 (9/16/2014) through the first quarter of 2016 (1/30/2016), being most of the period that Main Avenue has been a subsidiary of the Registrant. In its notification on May 25, 2016, ESI has declared that the doctor did not have the requisite relationship with the patients for whom he wrote the prescriptions and that, accordingly, the prescriptions were ~~not valid.~~stated Into ~~conclusion,~~be ~~ESI~~evidence ~~has indicated that it will not release any~~ of ~~the $3.55 million being held and, in addition, has demanded~~potential ~~repayment~~violations of ~~$12,155,159.97~~federal ~~almost all of which is due to the claimed “invalid Patient/Prescriber Relationship”~~law. ~~Finally, ESI has terminated Main Avenue’s Network Provider Agreement/Status.~~

~~Registrant’s~~The ~~Management~~Company is ~~considering~~evaluating ~~its~~the ~~options~~subpoena and ~~potential~~intends to fully ~~responses~~cooperate in the investigation. We cannot predict the eventual scope, duration or outcome of the investigation at this time.

~~Since~~At ~~receipt~~a meeting of the ~~notice~~Company’s Board of ~~default~~Directors, onheld June ~~April 26~~9, 2016, ~~from~~ the accounts receivable lender, Main Avenue has discontinued all new borrowings, has been seeking to develop a workout plan with the lender, and has implemented a repayment program which is already proceeding pending a mutually acceptable workout plan. Main Avenue continues with its business plan.Board:

Of(1) ~~the~~Authorized ~~$12,155,159.97,~~corporate ancounsel ~~estimated~~to ~~amount~~interview oflaw $1firms ~~million~~and ~~came~~promptly recommend a firm to ~~Main~~ ~~Avenue~~conduct ~~from~~an ~~Medi~~independent ~~Biotech~~review of the practices and isprocedures ~~being~~of ~~counterclaimed~~the inCompany and its subsidiaries, and report to the ~~pending~~Board; ~~lawsuit.~~and

(2)

Initiated reconsideration of the Company’s strategic business plan in preparation for potential implementation of recommendations of the independent review.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ScripsAmerica, Inc
Date: May 31, 2016	By: /s/ Brian Ettinger
Date: June 9, 2016	By: /s/ Brian Ettinger
	Brian Ettinger
	Chief Executive Officer

Filing Compare · ScripsAmerica, Inc.